Preferred Label : N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide;
MeSH note : Sch-503034 is the (1R,2S,5S)-isomer; an HCV protease inhibitor; structure in first
source;
CISMeF synonym : sch 503034; vicrtelis; boceprevir;
MeSH synonym : boceprevir;
MeSH hyponym : Sch503034; Sch-503034;
Is substance : O;
UNII : 89BT58KELH;
InChIKey : LHHCSNFAOIFYRV-DOVBMPENSA-N;
Origin ID : C512204;
UMLS CUI : C1738934;
ATC code(s)
CISMeF manual mappings
Exact mapping(s) to DCI
MeSH term(s) associated for indexing
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
http://www.has-sante.fr/portail/jcms/c_1751174/fr/victrelis
http://www.has-sante.fr/portail/jcms/c_1189486/victrelis
2014
false
France
French
evaluation of the transparency committee
guidelines for drug use
boceprevir
administration, oral
insurance, health, reimbursement
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
proline
protease inhibitors
protease inhibitors
hepatitis C, chronic
adult
treatment outcome
controlled clinical trials as topic
NS3 protein, hepatitis C virus
viral nonstructural proteins
drug therapy, combination
---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/victrelis-2846.html
2014
false
Canada
French
English
drug evaluation
evaluation of the transparency committee
boceprevir
polyethylene glycols
proline
interferon-alpha
recombinant proteins
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
drug therapy, combination
administration, oral
treatment outcome
hepatitis C, chronic
protease inhibitors
ribavirin
antiviral agents
peginterferon alfa-2b
costs and cost analysis
injections, subcutaneous
adult
clinical trials as topic
---
https://www.ema.europa.eu/medicines/human/EPAR/Victrelis
2012
false
United Kingdom
French
English
summary of product characteristics
package leaflet
drug evaluation
syndication feed
boceprevir
NS3 protein, hepatitis C virus
viral nonstructural proteins
drug evaluation, preclinical
drug interactions
fertility
breast feeding
pregnancy
drug therapy, combination
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
drug approval
treatment outcome
proline
administration, oral
adult
hepatitis C, chronic
protease inhibitors
protease inhibitors
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=67158000
2012
false
false
false
France
summary of product characteristics
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
capsules
---
http://www.has-sante.fr/portail/jcms/c_1255952/victrelis-boceprevir-inhibiteur-de-protease-du-vhc
2011
false
France
French
evaluation of the transparency committee
guidelines for drug use
boceprevir
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
administration, oral
hepatitis C, chronic
proline
insurance, health, reimbursement
drug therapy, combination
adult
protease inhibitors
protease inhibitors
treatment outcome
NS3 protein, hepatitis C virus
viral nonstructural proteins
randomized controlled trials as topic
---
Summary Basis of Decision (SBD) for VICTRELIS - Boceprevir, 200 mg capsule
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00303
2011
false
Canada
French
English
drug evaluation
boceprevir
drug approval
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
protease inhibitors
protease inhibitors
hepatitis C, chronic
risk assessment
treatment outcome
drug therapy, combination
adult
clinical trials, phase iii as topic
multicenter studies as topic
proline
---